4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
4D Molecular Therapeutics, Inc. (FDMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.30%.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.10%, a 10.87% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 4.10%, a 8.89% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.60%, a 6.98% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.60%, a 4.55% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.40%, a 4.35% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.60%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-13 | 4.30% 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | 4.10% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.60% 10-K · filed 2026-03-18 | |||
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-10 | 4.60% 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | 4.60% 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 4.60% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.40% 10-K · filed 2026-03-18 | |||
| 2024-09-30 | 4.50% 10-Q · filed 2025-11-10 | 4.50% 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-11 | 4.50% 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.60% 10-K · filed 2025-02-28 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-13 | 4.40% 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 4.00% 10-Q · filed 2024-08-08 | 4.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 4.00% 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | 3.90% 10-Q · filed 2023-11-09 | 3.90% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 3.60% 10-Q · filed 2023-08-09 | 3.60% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 2.00% 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-08 | 1.10% 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-11 | 1.10% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 1.10% 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-10 | 0.70% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 0.40% 10-Q · filed 2021-08-12 | 0.70% 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 0.70% 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |